pardoprunox pardoprunox pardoprunox (inn) (code name slv-308) is an antiparkinsonian drug developed by solvay for the treatment of parkinson's disease that reached phase iii clinical trials before being discontinued. it was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned as well. pardoprunoxclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status in general: uncontrolled identifiers iupac name 7-(4-methylpiperazin-1-yl)-3h-1,3-benzoxazol-2-one cas number269718-84-5pubchem cid6918524chemspider5293721unii5r72chp32scomptox dashboard (epa)dtxsid80949746 echa infocard100.206.783 chemical and physical dataformulac12h15n3o2molar mass233.271 g·mol−13d model (jsmol)interactive image smiles cl.o=c2oc1c(cccc1n2)n3ccn(c)cc3 pardoprunox acts as a d2 (pki = 8.1) and d3 receptor (pki = 8.6) partial agonist (ia = 50% and 67%, respectively) and 5-ht1a receptor (pki = 8.5) full agonist (ia = 100%). it also binds to d4 (pki = 7.8), α1-adrenergic (pki = 7.8), α2-adrenergic (pki = 7.4), and 5-ht7 receptors (pki = 7.2) with lower affinity. relative to other dopaminergic antiparkinsonian agents, pardoprunox is thought to have significantly less of a propensity for inducing certain side effects like dyskinesia and psychosis.